Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Contezolid - MicuRx Pharmaceuticals

Next Previous
X
Search
Drug Profile

Contezolid - MicuRx Pharmaceuticals

Alternative Names: MRX I; Youxitai

Latest Information Update: 26 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MicuRx Pharmaceuticals
  • Class Amines; Anti-infectives; Antibacterials; Antituberculars; Dihydropyridines; Fluorinated hydrocarbons; Foot disorder therapies; Oxazoles; Oxazolidinones; Skin disorder therapies
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase III Diabetic foot
  • No development reported Tuberculosis

Most Recent Events

  • 22 Sep 2023 Contezolid receives Fast Track designation for Diabetic foot [PO, Tablet] (Combination therapy, In the elderly, In adults) in USA
  • 22 Sep 2023 Contezolid receives Qualified Infectious Disease Product status for Diabetic foot in USA (PO, Tablet)
  • 19 Oct 2022 Adverse events data from a phase II and phase III trial in Skin and soft tissue infections presented at the ID Week (IDW-2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top